Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cullinan Therapeutics Inc (NQ: CGEM ) 15.78 +0.23 (+1.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 463,515 Open 15.71 Bid (Size) 15.78 (2) Ask (Size) 16.00 (5) Prev. Close 15.55 Today's Range 15.45 - 15.90 52wk Range 7.640 - 30.19 Shares Outstanding 199,873,683 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus October 16, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market September 25, 2024 Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... Via Benzinga Performance YTD +49.01% +49.01% 1 Month -1.99% -1.99% 3 Month -10.09% -10.09% 6 Month -44.44% -44.44% 1 Year +59.07% +59.07% More News Read More Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus September 17, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus September 16, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 September 14, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics to Participate in Upcoming Investor Conferences August 28, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst August 09, 2024 Via Benzinga CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024 August 08, 2024 Via InvestorPlace Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 08, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib June 01, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit May 24, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 May 23, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 May 15, 2024 Via InvestorPlace Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results May 15, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 29, 2024 Via Benzinga Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday April 29, 2024 Via Benzinga Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer April 29, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session April 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session April 26, 2024 Via Benzinga Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday April 26, 2024 Via Benzinga Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? April 24, 2024 Via Benzinga Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday April 24, 2024 Via Benzinga Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 April 24, 2024 From Cullinan Therapeutics, Inc. Via GlobeNewswire United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday April 17, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session April 17, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
